Skip to main content
Terug
Watch Compare

INTEGRATED BIOPHARMA INC

Datakwaliteit: 83%
INBP
OTC Manufacturing Chemicals
€ 0,28
€ 0,00 (0,00%)
6 months return
—
Momentum
Neutral
1Y earnings growth
621,43%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)621,43%
FCF Growth (3Y)29,58%

Kwaliteit

Return on Equity
-1,02%
Boven sectorgemiddelde (-54,47%)
ROIC1,41%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio5,03
Interest Coverage288,50

Waardering

PE (TTM)
-43,72
Onder sectorgemiddelde (-1,50)
P/B Ratio0,46
EV/EBITDA4,20
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Earnings grew 621,43% over the past year
Generating 2,82 M in free cash flow
ROIC of 1,41% — low return on invested capital

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Growth

Rev 5Y: N/A · Earnings 1Y: 621,43%
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) 621,43% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) -43,65%

Profitability

ROE: -1,02% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -206.000,0
ROE -1,02% ROA -0,84%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) 2,82 M
ROIC 1,41% FCF Growth (3Y) 29,58%

Safety

D/E: N/A · Current: 5,03
Debt / Equity N/A Current Ratio 5,03
Interest Coverage 288,50 Asset Turnover N/A
Working Capital 14,28 M Tangible Book Value 19,77 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 1 yrs

Valuation

P/E: -43,72 · EV/EBITDA: 4,20
P/E Ratio -43,72 Forward P/E N/A
P/B Ratio 0,46 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 4,20 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 31,33%
Market Cap 9,01 M Enterprise Value 3,69 M

Per Share

EPS: 0,00 · FCF/Share: 0,09
EPS (Diluted TTM) 0,00 Revenue / Share N/A
FCF / Share 0,09 OCF / Share 0,10
EPS CAGR (1Y) N/A EPS CAGR (5Y) -41,14%
EPS CAGR (10Y) -5,52%

Efficiency

FCF Conv: -1369,90% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion -1369,90%
SBC-Adj. FCF 2,63 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income 808.000,0 112.000,0 -34.000,0 3,84 M 8,01 M
EPS (Diluted) 0,03 0,00 0,00 0,12 0,25
Gross Profit 5,56 M 3,88 M 4,06 M 6,55 M 9,48 M
Operating Income 2,02 M 251.000,0 120.000,0 2,75 M 5,78 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses 3,54 M 3,63 M 3,94 M 3,81 M 3,70 M
D&A 318.000,0 319.000,0 351.000,0 336.000,0 337.000,0
Interest Expense 46.000,0 52.000,0 52.000,0 128.000,0 256.000,0
Income Tax 1,25 M 156.000,0 134.000,0 -1,24 M -766.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 24,90 M 26,21 M 25,43 M 25,25 M 25,44 M
Total Liabilities 4,58 M 6,97 M 6,57 M 6,68 M 11,11 M
Shareholders' Equity 20,32 M 19,24 M 18,86 M 18,58 M 14,33 M
Total Debt — — 0,0 186.000,0 3,64 M
Cash & Equivalents 3,62 M 1,68 M 1,32 M 331.000,0 210.000,0
Current Assets 18,76 M 17,88 M 16,37 M 16,63 M 18,00 M
Current Liabilities 4,25 M 6,12 M 4,83 M 5,26 M 9,24 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -43,7 -1,5
P/B 0,5 1,6
ROE % -1,0 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Dividendgeschiedenis

Recente betalingen per aandeel (nieuwste eerst).

Ex-dividend Betaling Bedrag / aandeel
Aug 19, 2008 — € 0,50